肺部给药作为一种非侵入性给药方式,在蛋白质、多肽类药物及肺部疾病药物的研究中得到快速发展. 具有低质量密度(〈0.4 g/cm^3)和较大几何粒径(〉10.0 μm)的载药高分子多孔微球,可以在肺部有效地沉积并且减少肺部巨噬细胞的吞噬,实现药物的局部或全身传递. 高分子多孔微球作为药物载体必须具备生物相容性和医用功能性2个基本特征. 本文主要综述了近年来对该基本特征进行生物学评价的研究进展,并对研究中存在的问题提出建议. 其中生物相容性评价内容涵盖细胞、整体、分子3个水平;医用功能性评价内容包括肺内沉积、肺部清除与吸收和载药高分子多孔微球的药效学研究进展.
As a non-invasive administration method, inhalable pulmonary drug delivery is suitable for the delivery of protein-and peptide-based drugs to treat lung diseases. Porous polymeric microspheres, which possess low mass densities (〈0.4 g/cm3) and large mean geometric diameters (〉10.0 μm), provide local or systemic drug delivery as they are deposited directly in the lung, and the uptake by alveolar macrophages is reduced. As inhalable drug carriers, porous polymeric microspheres should be biocompatible and offer in vitro drug-release properties. We review the progress in biological evaluation of these microspheres and propose solutions for the current problems. The biocompatibility evaluation of porous polymeric microspheres has been summarized at cellular, integrated and molecular levels. The medical function evaluation has been conducted on lung deposition, clearance and absorption within the lung and pharmacodynamics of drug loaded porous polymeric microspheres.